Lineage Therap (LCTX) Price & Analysis
LCTX Stock Chart & Stats
- Day’s Range
- ILA 322.90 - ILA 322.90
- 52-Week Range
- ILA 279.80 - ILA 666.00
- Previous Close
- ILA 322.90
- Volume
- 2,065
- Average Volume (3M)
- 6,722
- Market Cap
- ILS 795.28M
- Enterprise Value
- ILS 292.88M
- Total Cash (Recent Filing)
- ILS 50.83M
- Total Debt (Recent Filing)
- ILS 2.30M
- Price to Earnings (P/E)
- ―
- Beta
- 0.88
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- -9.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Scalable Manufacturing Platform
Validated GMP banking and production provides a reusable foundation for multiple cell types and programs. If the platform continues to support scalable, lower-cost allogeneic manufacturing, it can shorten development timelines, improve consistency, and strengthen Lineage’s long-term partnering appeal.
Strategic Partnerships And Milestone Potential
Established collaborations provide external validation, development support, and potential non-dilutive economics across the pipeline. Roche/Genentech and Demant involvement may reduce the burden of independently funding programs while preserving milestone and royalty opportunities if therapies advance.
Conservative Balance Sheet And Extended Runway
Low leverage limits near-term balance-sheet pressure and preserves flexibility while clinical programs progress. Combined with management’s projected runway into Q3 2028, the company has more time to pursue milestones and partnerships before needing additional financing, although execution remains important.
Bears Say
Persistent Cash Burn And Operating Losses
Ongoing negative operating and free cash flow means Lineage currently consumes capital rather than funding development internally. Persistent losses can reduce financial flexibility over time and increase reliance on financings, milestones, or partnerships to sustain clinical and platform investment.
Declining Collaboration Revenue
The revenue decline highlights the variability of Lineage’s collaboration-based business model before product commercialization. Lower recognized partnership revenue can make operating results less predictable, constrain internal funding capacity, and increase dependence on future milestones or new agreements.
Major ILT1 Manufacturing Scale Challenge
The substantially higher cell requirement creates a material technical and execution hurdle for ILT1. Lower islet-cell proliferative capacity and the need to scale production could delay development, raise manufacturing complexity, and limit the program’s ability to progress efficiently toward clinical use.
Lineage Therap News
LCTX FAQ
What was Lineage Therap’s price range in the past 12 months?
What is Lineage Therap’s market cap?
When is Lineage Therap’s upcoming earnings report date?
How were Lineage Therap’s earnings last quarter?
Is Lineage Therap overvalued?
Does Lineage Therap pay dividends?
What is Lineage Therap’s EPS estimate?
How many shares outstanding does Lineage Therap have?
What happened to Lineage Therap’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lineage Therap?
What is the TipRanks Smart Score and how is it calculated?
Lineage Therap Stock Smart Score
Company Description
Lineage Therap
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brian Culley
- Employees
- 75
- Website
- www.lineagecell.com
- Address
- 2173 Salk Avenue, Carlsbad, CA, 92008, US
Lineage Therap (LCTX) Earnings & Revenues
LCTX Earnings Call
Earnings Call SentimentNeutral
The call presented meaningful technical and strategic progress: demonstrated scalable GMP manufacturing (AlloSCOPE), rapid internal pipeline expansion (COR1, ILT1, ReSonance), and partnership validation (Roche/Genentech, Demant). Financial reporting showed an apparent improvement to net income, extension of cash runway into Q3 2028, and an incremental $4.6M ATM raise. However, material weaknesses and near-term risks remain: Q2 revenue dropped substantially (~60.7% YoY), reported profitability was driven by noncash accounting items, cash runway still depends on contingent exercises/milestones, OpRegen advancement timing is dependent on partner-driven surgical optimization, and ILT1 faces major manufacturing scale challenges. Overall, positives around technology, partnerships and program breadth are tempered by funding, revenue dynamics and technical/partner-dependent execution risks.
View all IL:LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 3 | 9 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 8 | 0 | 4 |